HighTower Advisors’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $604K | Buy |
5,309
+9
| +0.2% | +$1.02K | ﹤0.01% | 2353 |
|
|
2025
Q1 | $557K | Sell |
5,300
-242
| -4% | -$25.4K | ﹤0.01% | 2355 |
|
|
2024
Q4 | $594K | Buy |
5,542
+400
| +8% | +$42.9K | ﹤0.01% | 2324 |
|
|
2024
Q3 | $518K | Buy |
5,142
+266
| +5% | +$26.8K | ﹤0.01% | 2372 |
|
|
2024
Q2 | $412K | Buy |
4,876
+262
| +6% | +$22.1K | ﹤0.01% | 2453 |
|
|
2024
Q1 | $337K | Hold |
4,614
| – | – | ﹤0.01% | 2577 |
|
|
2023
Q4 | $329K | Buy |
4,614
+47
| +1% | +$3.35K | ﹤0.01% | 2619 |
|
|
2023
Q3 | $275K | Buy |
4,567
+1,675
| +58% | +$101K | ﹤0.01% | 2655 |
|
|
2023
Q2 | $208K | Buy |
2,892
+122
| +4% | +$8.78K | ﹤0.01% | 2822 |
|
|
2023
Q1 | $203K | Buy |
+2,770
| New | +$203K | ﹤0.01% | 2726 |
|
|
2022
Q4 | – | Sell |
-4,756
| Closed | -$256K | – | 3176 |
|
|
2022
Q3 | $256K | Buy |
4,756
+5
| +0.1% | +$269 | ﹤0.01% | 2425 |
|
|
2022
Q2 | $265K | Hold |
4,751
| – | – | ﹤0.01% | 2422 |
|
|
2022
Q1 | $333K | Sell |
4,751
-124
| -3% | -$8.69K | ﹤0.01% | 2423 |
|
|
2021
Q4 | $469K | Buy |
4,875
+29
| +0.6% | +$2.79K | ﹤0.01% | 2186 |
|
|
2021
Q3 | $419K | Buy |
4,846
+32
| +0.7% | +$2.77K | ﹤0.01% | 2174 |
|
|
2021
Q2 | $394K | Sell |
4,814
-14
| -0.3% | -$1.15K | ﹤0.01% | 2182 |
|
|
2021
Q1 | $458K | Sell |
4,828
-117
| -2% | -$11.1K | ﹤0.01% | 2019 |
|
|
2020
Q4 | $308K | Buy |
4,945
+67
| +1% | +$4.17K | ﹤0.01% | 1885 |
|
|
2020
Q3 | $290K | Buy |
4,878
+119
| +3% | +$7.08K | ﹤0.01% | 1833 |
|
|
2020
Q2 | $332K | Buy |
+4,759
| New | +$332K | ﹤0.01% | 1655 |
|
|
2018
Q4 | – | Sell |
-1,587
| Closed | -$272K | – | 2172 |
|
|
2018
Q3 | $272K | Buy |
+1,587
| New | +$272K | ﹤0.01% | 1774 |
|
|
2017
Q4 | – | Sell |
-7,172
| Closed | -$613K | – | 2181 |
|
|
2017
Q3 | $613K | Buy |
+7,172
| New | +$613K | 0.01% | 1334 |
|